Acadia-Zydus Nuplazid Patent Fight Ends, RBC Sees Exclusivity to 2038
ACAD is trading near its 52-week low of $19.566 (2.5% above the low).
Summary
Acadia and Zydus filed a joint stipulation to dismiss all claims in the Nuplazid patent litigation, just weeks before the November 2 trial. RBC says the settlement likely preserves exclusivity through around 2038, removing a key overhang on Acadia's largest revenue driver. Nuplazid is tracking to ~$780M in FY26 sales, near the company's ~$1B peak guidance. This follows prior wins against MSN and Aurobindo, and comes after the remlifanserin Phase 3 miss in September that crushed the stock. The base business now looks overly discounted, and this de-risks Nuplazid's tail revenue.
At the time of this announcement, ACAD was trading at $20.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $19.57 to $30.96. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.